A Randomized Phase 3 Study of MRTX849 in Combination with Cetuximab Versus Chemotherapy in Patients with Advanced Colorectal Cancer with KRAS G12C Mutation with Disease Progression On or After Standard First-Line Therapy

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Advanced Colorectal Cancer
  • Age: Between 18 - 100 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Histologically confirmed diagnosis of colorectal carcinoma with KRAS G12C mutation in tumor tissue. 2) Prior receipt of first-line treatment in the advanced disease setting with a fluoropyrimidine-based chemotherapy regimen containing either oxaliplatin or irinotecan, and radiographically documented progression of disease on or after treatment. 3) Candidacy to receive treatment with cetuximab in accordance with the local product label, with the exception that patients must have documented KRAS G12C mutation and may or may not have demonstrated tumor positivity for EGFR-expression. 4) Presence of evaluable or measurable disease per RECIST 1.1 and able to provide a sufficient amount of representative tumor specimen (primary or metastatic, archival or newly obtained) for central laboratory testing of KRAS G12C mutation status (minimum of 5 slides, preferably 15 slides).

You may not be eligible for this study if the following are true:

  • 1) Prior treatment with both an oxaliplatin- and irinotecan-based regimen for CRC in the adjuvant and/or later treatment settings. 2) Prior treatment with a therapy targeting KRAS G12C mutation (e.g., AMG 510). 3) Prior treatment with an anti-EGFR antibody (e.g., cetuximab or panitumumab). 4) Most recent prior anticancer therapy (e.g., chemotherapy, antiangiogenic therapy or radiation therapy) discontinued within 2 weeks before the date of randomization.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.